Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Therapy-Related AML (t-AML), a Heterogeneous Disease: Multicenter Analysis on Biological and Clinical Differences between Cases Following Breast Cancer and Lymphoma Treatment

Giambattista Bertani, MD, Fabio Guolo, MD, Valentina Mancini, MD, Rosa Greco, MD, Paola Minetto, MD PhD, Monica Passannante, MD, Roberto Massimo Lemoli, MD, Roberto Cairoli

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-138866

Published: 2020

Journal Articles

Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Paola Minetto, MD PhD, Anna Candoni, Fabio Guolo, MD, Marino Clavio, MD, Maria Elena Zannier, MD, Maurizio Miglino, PhD, Maria Vittoria Dubbini, MD, Anna Sicuranza, PhD, Sara Ciofini, Elisabetta Tedone, Nicoletta Colombo, PhD, Girolamo Pugliese, Filippo Ballerini, MD, Michele Cea, Monica Bocchia, Renato Fanin, MD, Roberto Massimo Lemoli, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142887

Published: 2020

Journal Articles

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Blood (2019) 134 (Supplement_1): 3828.

https://doi.org/10.1182/blood-2019-131303

Published: 2019

Journal Articles

Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients

Fabio Guolo, MD, Paola Minetto, MD, Luana Fianchi, MD, Michela Rondoni, MD, Giulia Daghia, MD, Stefano D'Ardia, MD, Monica Morselli, MD, Crescenza Pasciolla, MD, Francesca Pavesi, MD, Barbara MD Scappini, Francesco Lanza, MD, Marco Gobbi, MD, Livio Pagano, MD, Felicetto Ferrara, MD, Roberto Massimo Lemoli, MD

Blood (2019) 134 (Supplement_1): 1363.

https://doi.org/10.1182/blood-2019-131329

Published: 2019

Journal Articles

Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1365.

https://doi.org/10.1182/blood-2019-131420

Published: 2019

Journal Articles

Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma

Fabio Guolo, MD, Paola Minetto, MD, Filippo Ballerini, MD, Elisabetta Tedone, Paola Contini, Rosa Mangerini, Alessandra Bo, MD, Maria Carla De Luigi, MD, Paolo Carlier, MD, Alberto Serio, Paolo Strada, MD, Silvia Luchetti, Marco Gobbi, MD, Emanuela Marcenaro, PhD, Roberto Massimo Lemoli, MD

Blood (2019) 134 (Supplement_1): 3231.

https://doi.org/10.1182/blood-2019-130740

Published: 2019

Journal Articles

Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs

Paola Minetto, MD, Debora Soncini, PhD, Fabio Guolo, MD, Samantha Ruberti, BSc, PhD, Veronica Retali, Paola Contini, Nadia Bisso, MD, Nikki Di Felice, MD, Giulia Rivoli, MD, Antonia Cagnetta, MD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD, Michele Cea, MD

Blood (2018) 132 (Supplement 1): 3221.

https://doi.org/10.1182/blood-2018-99-119622

Published: 2018

Journal Articles

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

Fabio Guolo, MD, Paola Minetto, MD, Annalisa Kunkl, MD, Elisabetta Tedone, Marino Clavio, MD, Maurizio Miglino, PhD, Fabrizio Caviglia, Nicoletta Colombo, PhD, Antonia Cagnetta, MD, Michele Cea, MD, Filippo Ballerini, MD, Jean Louis Ravetti, MD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2018) 132 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2018-99-118984

Published: 2018

Journal Articles

Feasibility of High Doses Peg-Asparaginase Administration in a Cohort of Adult Acute Lymphoblastic Leukemia Patients

Paola Minetto, MD, Nadia Bisso, MD, Fabio Guolo, MD, Marino Clavio, MD, Riccardo Marcolin, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2018) 132 (Supplement 1): 5164.

https://doi.org/10.1182/blood-2018-99-119787

Published: 2018

Journal Articles

Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2018-99-118901

Published: 2018

Journal Articles

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

Fabio Guolo, MD, Paola Minetto, MD, Marino Clavio, MD, Nicoletta Colombo, PhD, Annalisa Kunkl, MD, Enrico Carminati, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Emanuele Angelucci, Roberto M Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 3316.

https://doi.org/10.1182/blood.V130.Suppl_1.3316.3316

Published: 2017

Journal Articles

Patient and Therapy-Related Factors Affecting the Toxicity of Pegylated-Asparaginase for the Treatment of Adult Acute Lymphoblastic Leukemia

Paola Minetto, MD, Nadia Bisso, MD, Fabio Guolo, MD, Marino Clavio, MD, Elisa Coviello, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 1297.

https://doi.org/10.1182/blood.V130.Suppl_1.1297.1297

Published: 2017

Journal Articles

Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma

Giulia Bartalucci, MD, Elisa Coviello, MD, Fabio Guolo, MD, Paola Minetto, MD, Massimiliano Gambella, Giulia Rivoli, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Alberto Fabbri, MD, Roberto M Lemoli, MD, Monica Bocchia, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 2851.

https://doi.org/10.1182/blood.V130.Suppl_1.2851.2851

Published: 2017

Journal Articles

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Simona Matarese, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Antonia Cagnetta, MD, Michele Cea, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 5047.

https://doi.org/10.1182/blood.V130.Suppl_1.5047.5047

Published: 2017

Journal Articles

Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors

Paola Minetto, MD, Debora Soncini, PhD, Antonia Cagnetta, MD, Fabio Guolo, MD, Veronica Retali, Giulia Rivoli, MD, Nadia Bisso, MD, Nikki Di Felice, MD, Maurizio Miglino, PhD, Letizia Canepa, MD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD, Michele Cea

Blood (2017) 130 (Supplement 1): 1796.

https://doi.org/10.1182/blood.V130.Suppl_1.1796.1796

Published: 2017

Journal Articles

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Filippo Ballerini, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Giordana Pastori, MD, Simona Matarrese, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Andrea Bacigalupo, MD, Roberto Massimo Lemoli, MD, Maurizio Miglino, PhD, Marco Gobbi, MD

Blood (2016) 128 (22): 2895.

https://doi.org/10.1182/blood.V128.22.2895.2895

Published: 2016

Journal Articles

CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents

Michele Cea, MD, Antonia Cagnetta, MD, Debora Soncini, PhD, Paola Minetto, MD, Micaela Bergamaschi, MD, Giulia Rivoli, MD, Letizia Canepa, MD, Marco Gobbi, MD, Roberto M Lemoli, MD

Blood (2016) 128 (22): 5671.

https://doi.org/10.1182/blood.V128.22.5671.5671

Published: 2016

Journal Articles

Finding the Best Therapy for Elderly Frail AML Patients: A Retrospective Comparison of 5-Azacytidine and Intensive Approach

Giordana Pastori, MD, Fabio Guolo, MD, Paola Minetto, MD, Marino Clavio, MD, Enrico Balleari, MD, Nicoletta Colombo, Biologist, Giulia Rivoli, MD, Lisette Del Corso, MD, Filippo Ballerini, MD, Livia Giannoni, MD, Laura Mitscheunig, MD, Clara Dellepiane, Daniela Guardo, MD, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2016) 128 (22): 5202.

https://doi.org/10.1182/blood.V128.22.5202.5202

Published: 2016

Journal Articles

Combining Flow Cytometry and Molecular Assessment Improves the Prognostic Value of Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia

Fabio Guolo, MD, Paola Minetto, MD, Federica Galaverna, MD, Daniela Guardo, MD, Nicoletta Colombo, PhD, Annalisa Kunkl, MD, Marino Clavio, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD, Andrea Bacigalupo, MD

Blood (2016) 128 (22): 521.

https://doi.org/10.1182/blood.V128.22.521.521

Published: 2016

Journal Articles

SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Debora Soncini, PhD, Paola Minetto, MD, Davide Lovera, MD, Fabio Guolo, MD, Nicoletta Colombo, PhD, Filippo Ballerini, MD, Marino Clavio, MD, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto M Lemoli, MD

Blood (2016) 128 (22): 5222.

https://doi.org/10.1182/blood.V128.22.5222.5222

Published: 2016

NARROW

Therapy-Related AML (t-AML), a Heterogeneous Disease: Multicenter Analysis on Biological and Clinical Differences between Cases Following Breast Cancer and Lymphoma Treatment

Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients

Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia

Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma

Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

Feasibility of High Doses Peg-Asparaginase Administration in a Cohort of Adult Acute Lymphoblastic Leukemia Patients

Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

Patient and Therapy-Related Factors Affecting the Toxicity of Pegylated-Asparaginase for the Treatment of Adult Acute Lymphoblastic Leukemia

Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents

Finding the Best Therapy for Elderly Frail AML Patients: A Retrospective Comparison of 5-Azacytidine and Intensive Approach

Combining Flow Cytometry and Molecular Assessment Improves the Prognostic Value of Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia

SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only